---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020569"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:18:52.245408+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tempest Q1 2023 net loss $7.6M ($0.55/shr); positive TPST-1120 HCC data highlighted

## Summary
- Net loss $7.6M ($0.55 per share) vs $8.5M ($1.18) in Q1 2022; cash $22.9M, runway through Q2 2024.
- TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% control, 74.4% relative improvement.
- Confirmed ORR 17.5% (7/40) vs 10.3% control, 69.9% relative improvement; 80% TPST-1120 arm on study vs 50% control.
- TPST-1495 enrolling endometrial cancer arm with pembrolizumab; TREX1 inhibitor preclinical data presented at AACR.
- Expects updated TPST-1120 data from Roche; plans to report TPST-1495 data at ASCO 2023.

## SEC filing metadata
- accession: 0000950170-23-020569
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/0000950170-23-020569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/tpst-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020569
- JSON: https://secwatch.observer/filing/0000950170-23-020569.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020569.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively, EPS $0.55.
  - Period: quarter ended March 31, 2023
  - Net income: Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively
  - EPS: $0.55
  - Result: reported results
  source text: Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017023020569/0000950170-23-020569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.